ABSTRACT
BACKGROUND: Few studies have directly compared virus-specific antibodies and their neutralizing capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild type (WT) and circulating variants of concern despite the reported high efficacy of messenger RNA (mRNA)- and vector-based vaccines. OBJECTIVE: We assessed SARS-CoV-2 spike protein region 1 (S1)-specific antibodies of BNT162b2, mRNA-1273, and ChAdOx1 vaccinated as well as convalescent coronavirus disease 2019 (COVID-19) patients. We also determined the neutralization ability against SARS-CoV-2 WT and B.1.1.7 (Alpha), B1.1.7 E484K (Alpha-E484K), B.1.351 (Beta), and B.1.617.2 (Delta) variants. METHODS: Serum samples of 107 fully vaccinated or convalescent individuals were analyzed for anti-SARS-CoV-2-S1 IgG and IgA as well as for total anti-SARS-CoV-2 receptor binding domain Ig. Furthermore, neutralization capacity as 50% and 90% neutralization titer values against SARS-CoV-2 WT virus and circulating variants were determined. RESULTS: We observed a robust IgG response in all participants; however, the highest titers were detected in mRNA-based vaccine recipients. In case of serum IgA responses, the difference between mRNA- and vector-based vaccines or convalescent patients was even more pronounced. Interestingly, all 3 vaccines could neutralize all tested variants of concern in addition to WT virus, but in some individuals, only low or no neutralization, especially against Alpha-E484K and the Delta variant, was detected. CONCLUSION: Our study of the efficacy of various COVID-19 vaccines found that mRNA-1273 had the highest neutralization abilities compared to BNT162b2 and ChAdOx1. COVID-19 convalescent patients demonstrated the most heterogeneous range of antibody titers and neutralization abilities, making it hard to assess protection. Furthermore, a significant positive relation between antibodies and the 50% neutralization titer values for immunized and convalescent individuals was determined.
Subject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Neutralizing , Antibodies, Viral , BNT162 Vaccine , COVID-19/prevention & control , COVID-19 Vaccines , Humans , Immunoglobulin A , Immunoglobulin G , RNA, Messenger , Spike Glycoprotein, CoronavirusABSTRACT
BACKGROUND: The association of Chlamydophila pneumoniae infection with essential hypertension is known but its association with hypertension during pregnancy is controversial. Hence, this study aimed to explore the association of C. pneumoniae infection with hypertension during pregnancy. The objectives were to compare the presence of C. pneumoniae DNA in trophoblastic cells of placenta between hypertensive and normotensive pregnant women and to find out the presence of inflammatory marker (HSP-60) and the seropositivity (IgG and IgA) of C. pneumoniae in them. MATERIALS AND METHODS: The study was conducted at a tertiary-care institute, in South-India between 2018 and 2020. Women with hypertension during pregnancy were study group (75) and normotensive pregnant women were control group (75). IgG and IgA antibodies, HSP-60 against C. pneumoniae were estimated by ELISA from 5 ml of venous blood. C. pneumoniae DNA was extracted from placental tissue after delivery and tested by RT-PCR. STATISTICAL ANALYSIS: The association between C. pneumoniae DNA, seropositivity and hypertension was determined by student test and univariate regression analysis. RESULTS: C. pneumoniae DNA was detected in the placenta of 29.3% with hypertension and none in controls and the odds was 6.5 (OR-6.5, CI 95%). HSP-60 was elevated in women with preeclampsia and not in gestational hypertension and controls. IgA was not detected and IgG was positive in 15.2% of women with preeclampsia. CONCLUSION: There is a significant association between C. pneumoniae infection and hypertension during pregnancy and further studies are required to fulfil the Koch's postulates to prove or disprove it as a causative agent.
Subject(s)
Chlamydophila pneumoniae , Hypertension, Pregnancy-Induced , Antibodies, Bacterial , Case-Control Studies , Female , Humans , Placenta , PregnancyABSTRACT
INTRODUCTION: The discovery of two types of Epstein-Barr virus (EBV) (EBV-1 and EBV-2) that have different biological properties stimulated the search for neoplasms associated with each type of the virus. The aim of the work is to study the nature of the association of nasopharyngeal cancer (NPC) with EBV-1 and EBV-2, serological activity for each viral type and the concentration of EBV DNA in the blood plasma of two gender, age and ethnic groups of NPC patients that represent geographically and climatically different regions of Russia,. MATERIALS AND METHODS: In the blood plasma of patients with NPC and other non- EBV associated tumors of oral cavity (OTOCEBV-) from the North Caucasian (NCFD) and Central (CFD) Federal Districts of Russia, the types of EBV and the concentration of viral DNA were determined using respectively «nested¼ and real time PCR; titers of IgG and IgA antibodies to viral capsid antigen (VCA) were measured in indirect immunofluorescence assay. RESULTS: The blood plasma samples testing showed that NPC and OTOCEBV- patients were infected with both types of EBV in approximately equal proportions. In two groups of NPC patients infected with one of the virus types only, EBV-1 or EBV-2, respectively, no statistically significant differences were found between the geometric mean values of IgG and IgA anti-EBV antibody titers and viral DNA concentrations in blood plasma. The distribution of virus types was not affected by either patient gender or ethnogeographic origin. The difference was found only between age groups: EBV-2 dominated in NPC patients up to 60 years, and EBV-1 was prevalent in patients over 60 years. CONCLUSION: The lack of the predominance of one of EBV types in NPC patients that are the representatives of different ethnic groups from geographically and climatically different regions, suggests that none of these factors play an important role in the NPC carcinogenesis. Evidently, each type of EBV, EBV-1 or EBV-2, if the necessary conditions arise, are able to exhibit its oncogenic potential to initiate tumor development.